Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

JMU scientists crystallize new inhibitory antibodies targeting sclerostin

Osteoporosis particularly affects elderly women: the bone's structure weakens and the risk of suffering fractures rises.

2 Sep 2016

Mayo Clinic offers CDC’s Zika virus screening test

Mayo Clinic will offer the Zika virus antibody test developed by the Centers for Disease Control and Prevention.

1 Sep 2016

Added benefit not proven for new combination therapy in multiple myeloma

The monoclonal antibody elotuzumab has been approved in combination with lenalidomide and dexamethasone since May 2016 for further treatment of multiple myeloma in adults who have received at least one previous treatment.

1 Sep 2016

Monoclonal antibody removes brain amyloid plaques in patients with Alzheimer's disease

Scientists at Neurimmune today described results from the Phase 1b PRIME clinical trial of the monoclonal antibody aducanumab.

1 Sep 2016

LJI researchers reveal unanticipated way by which neutrophils defend against invading pathogens

As an arm of the innate immune system, white blood cells called neutrophils form the first line of defense against invading pathogens.

31 Aug 2016

MedUni Vienna scientists aim to identify prognostic markers for cutaneous lymphomas

Primary cutaneous lymphomas, cancers of the lymphatic system, occur in the skin and originate either from T-lymphocytes (T-cell lymphomas, incidence 75%) or in B-cell lymphocytes (B-cell lymphomas, 25%).

30 Aug 2016

Researchers find better way to purify liver cells made from induced pluripotent stem cells

A research team including developmental biologist Stephen A. Duncan, D. Phil., SmartState Chair of Regenerative Medicine at the Medical University of South Carolina, has found a better way to purify liver cells made from induced pluripotent stem cells (iPSCs).

30 Aug 2016

Janssen seeks to extend DARZALEX license to benefit more multiple myeloma patients

Janssen-Cilag International NV has announced the submission of a Type II variation application to the European Medicines Agency (EMA), seeking to broaden the existing marketing authorisation for the immunotherapy DARZALEX® (daratumumab) to include treatment of adult patients with relapsed multiple myeloma who have received at least one prior therapy. The expanded indication is based on daratumumab in combination with lenalidomide (an immmunomodulatory agent) and dexamethasone, or bortezomib (a PI) and dexamethasone.

29 Aug 2016

Fiocruz to start phase II clinical trials of novel vaccine for schistosomiasis

The Oswaldo Cruz Foundation at Rio de Janeiro, Brazil, will start the phase II clinical trials of a vaccine for schistosomiasis, called 'Sm14 Vaccine'.

26 Aug 2016

CPhI Pre-Connect Congress to provide insights on major developments in pharmaceutical industry

CPhI Worldwide, organized by UBM EMEA, announces the upcoming trends in the 8th edition of the CPhI Pre-Connect Congress, taking place on October 3rd.

26 Aug 2016

Chromatrap develops new range of optimised ChIP assay kits for genetic research

Chromatrap is a pioneer in the development of solid-state filter-based technology that significantly enhances and accelerates the important epigenetic research tool of chromatin immunoprecipitation (ChIP).

From Chromatrap® - Porvair Sciences Ltd 26 Aug 2016

Research findings pave way to effective strategies for treatment of visceral leishmaniasis

A study shows that stimulating the production of interleukin-17A (IL-17A), one of the cytokines released by cells of the immune system, can be an effective strategy for the treatment of visceral leishmaniasis, considered one of the six most important parasitic diseases affecting humans.

25 Aug 2016

Researchers discover novel pathway for immune recovery following bone-marrow transplantation

New research has shown how a cell surface molecule, Lymphotoxin β receptor, controls entry of T-cells into the thymus; and as such presents an opportunity to understanding why cancer patients who undergo bone-marrow transplant are slow to recover their immune system.

25 Aug 2016

Three like-minded nonprofits collaborate to launch immunotherapy clinical trial for pediatric brain tumors

A Kids' Brain Tumor Cure Foundation, Solving Kids' Cancer and the Ty Louis Campbell Foundation announce their joint financial support of a Phase 1 clinical trial to test the safety and efficacy of combination checkpoint inhibitors in the treatment of children with brain tumors.

25 Aug 2016

Assigning barcode to stem cells makes it possible to monitor large blood cell populations

By assigning a barcode to stem cells, researchers at Lund University in Sweden have made it possible to monitor large blood cell populations as well as individual blood cells, and study the changes over time.

24 Aug 2016

Checkpoint inhibitor for treatment of NSCLC patients shows indication of added benefit

Nivolumab has been approved since April 2016 as a checkpoint inhibitor for the treatment of adults with locally advanced or metastatic nonsquamous non-small-cell lung cancer (NSCLC) who have already undergone chemotherapy.

19 Aug 2016

Added benefit not proven for orphan drug in treatment of adults with stomach cancer

Ramucirumab (trade name: Cyramza) is a monoclonal antibody, which blocks a receptor, reducing the growth of blood vessels and so reducing blood supply to the tumours.

19 Aug 2016

New NIST Standard Reference Material helps ensure accurate measurements of HER2 breast cancer gene

A new measurement standard developed by the National Institute of Standards of Technology has been used successfully by the Frederick National Laboratory for Cancer Research to check the performance of next-generation DNA-sequencing technologies for evaluating gene variations associated with an increased risk of breast cancer.

18 Aug 2016

FDA grants Orphan Drug Designation to CD4CAR therapy for treatment of peripheral T-cell lymphoma

iCell Gene Therapeutics today (Aug. 11) announced that the Food and Drug Administration has granted Orphan Drug Designation for its chimeric antigen receptor engineered T-cells directed against the target protein CD4 (CD4CAR) for the treatment of peripheral T-cell lymphoma (PTCL).

12 Aug 2016

New drug provides considerable added benefit in treating adults with advanced renal cell cancer

Nivolumab has been approved since April 2016 as a checkpoint inhibitor for the treatment of adults with advanced renal cell cancer who have already undergone prior therapy.

11 Aug 2016

Antibody News and Research

Further Reading

JMU scientists crystallize new inhibitory antibodies targeting sclerostin

Mayo Clinic offers CDC’s Zika virus screening test

Added benefit not proven for new combination therapy in multiple myeloma

Monoclonal antibody removes brain amyloid plaques in patients with Alzheimer's disease

LJI researchers reveal unanticipated way by which neutrophils defend against invading pathogens

MedUni Vienna scientists aim to identify prognostic markers for cutaneous lymphomas

Researchers find better way to purify liver cells made from induced pluripotent stem cells

Janssen seeks to extend DARZALEX license to benefit more multiple myeloma patients

Fiocruz to start phase II clinical trials of novel vaccine for schistosomiasis

CPhI Pre-Connect Congress to provide insights on major developments in pharmaceutical industry

Chromatrap develops new range of optimised ChIP assay kits for genetic research

Research findings pave way to effective strategies for treatment of visceral leishmaniasis

Researchers discover novel pathway for immune recovery following bone-marrow transplantation

Three like-minded nonprofits collaborate to launch immunotherapy clinical trial for pediatric brain tumors

Assigning barcode to stem cells makes it possible to monitor large blood cell populations

Checkpoint inhibitor for treatment of NSCLC patients shows indication of added benefit

Added benefit not proven for orphan drug in treatment of adults with stomach cancer

New NIST Standard Reference Material helps ensure accurate measurements of HER2 breast cancer gene

FDA grants Orphan Drug Designation to CD4CAR therapy for treatment of peripheral T-cell lymphoma

New drug provides considerable added benefit in treating adults with advanced renal cell cancer

Immunology eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo